The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Open accessAbstract
We have demonstrated previously that the oncoprotein Mdm2 has a ubiquitin ligase activity for the tumor suppressor p53 protein. In the present study, we characterize this ubiquitin ligase activity of Mdm2. We first demonstrate the ubiquitination of several p53 point mutants and deletion mutants by Mdm2. The point mutants, which cannot bind to Mdm2, are not ubiquitinated by Mdm2. The ubiquitination of the C-terminal deletion mutants, which contain so-called Mdm2-binding sites, is markedly decreased, compared with that of wild-type p53. The binding of Mdm2 to p53 is essential for ubiquitination, but p53's tertiary structure and/or C-terminal region may also be important for this reaction. DNA-dependent protein kinase is known to phosphorylate p53 on Mdm2-binding sites, where DNA damage induces phosphorylation, and p53 phosphorylated by this kinase is not a good substrate for Mdm2. This suggests that DNA damage-induced phosphorylation stabilizes p53 by inhibiting its ubiquitination by Mdm2. We further investigated whether the tumor suppressor p19(ARF) affects the ubiquitin ligase activity of Mdm2 for p53. The activity of p19(ARF)-bound Mdm2 was found to be lower than that of free Mdm2, suggesting that p19(ARF) promotes the stabilization of p53 by inactivating Mdm2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the tumor suppressor genes that stabilize p53 (Trp53) via inactivation of Mdm2 in response to a variety of oncogenic stresses (Honda and Yasuda, 1999;Brummelkamp et al., 2002;Lingbeek et al., 2002;Kim and Sharpless, 2006).”
From Tbx3 controls the fate of hepatic progenitor cells in liver development by suppressing p19ARF expression (2008) · cites this paper as Honda and Yasuda, 1999
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Tbx3 is known as a transcriptional repressor for p19 ARF (Cdkn2a -Mouse Genome Informatics) and p14 ARF (the human ortholog of p19 ARF )”
From Tbx3 controls the fate of hepatic progenitor cells in liver development by suppressing p19ARF expression (2008) · cites this paper as Honda and Yasuda, 1999
Experimental — accuracy not yet measuredIn the citing paper
“These data suggested that transfected GFP-Mdm2 is a labile protein that is a target for degradation (20,21) and, furthermore, that PKB phosphorylation is required for protecting Mdm2 from proteasome-dependent destruction, thus increasing Mdm2 stability.”
From Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation (2004) · cites this paper as [20]
In the citing paper
“Mdm2 harbors a self-and p53specific E3 ubiquitin ligase activity within its evolutionarily conserved C-terminal RING finger domain, which mediates p53 ubiquitination and rapid degradation by the 26 S proteasome (20,21).”
From Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation (2004) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“When Mdm2 cDNA is transfected into human cells, p53 degradation is accelerated (Haupt et al., 1997; Kubbutat et al., 1997).”
BackgroundKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., & Howley, P. M. (1993) · Cell · doi:10.1016/0092-8674(93)90384-3 · Cited by 2,416
p53: puzzle and paradigm.Preprint
Ko, L. J., & Prives, C. L. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,346
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Cited by
Sorted by citations
Items 201–300 of 721
Eymin, B., Gazzéri, S., Brambilla, C., & Brambilla, E. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205359 · Cited by 104
Fátyol, K., & Szalay, A. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102847200 · Cited by 108
Inoue, K., Wen, R., Rehg, J. E., Adachi, M., Cleveland, J. L., Roussel, M. F., & Sherr, C. J. (2000) · Genes & Development · doi:10.1101/gad.14.14.1797 · Cited by 107
Wang, X., Zalcenstein, A., & Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401181 · Cited by 107
Lai, Z., Yang, T., Kim, Y. B., Sielecki, T. M., Diamond, M. A., Strack, P. R., Rolfe, M., Caligiuri, M., Benfield, P. A., Auger, K. R., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212428599 · Cited by 106
Regulation of p53 - insights into a complex process
Boehme, K. A., & Blattner, C. (2009) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409230903401507 · Cited by 107
NM23-H1 Tumor Suppressor and Its Interacting Partner STRAP Activate p53 Function
Jung, H., Seong, H., & Ha, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705181200 · Cited by 105
AMP-Activated Protein Kinase Induces p53 by Phosphorylating MDMX and Inhibiting Its Activity
He, G., Zhang, Y.-W., Lee, J., Zeng, S. X., Wang, Y. V., Luo, Z., Dong, X. C., Viollet, B., Wahl, G. M., & Lu, H. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00670-13 · Cited by 107
Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Chesnokova, V., Zonis, S., Rubinek, T., Yu, R., Ben-Shlomo, A., Kovács, K., Wawrowsky, K., & Melmed, S. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0974 · Cited by 106
c-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53
Sionov, R. V., Moallem, E., Berger, M., Kazaz, A., Gerlitz, O., Ben‐Neriah, Y., Oren, M., & Haupt, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8371 · Cited by 104
Sumoylation of Mdm2 by Protein Inhibitor of Activated STAT (PIAS) and RanBP2 Enzymes
Miyauchi, Y., Yogosawa, S., Honda, R., Nishida, T., & Yasuda, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208319200 · Cited by 102
Self-citationRegulation of transcription factors by protein degradation
Desterro, J. M. P., Rodríguez, M. S., & Hay, R. T. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000760 · Cited by 101
Pinyol, M., Hernández, L., Martı́nez, A., Cobo, F., Hernandez, S. F., Beà, S., López‐Guillermo, A., Nayach, I., Palacı́n, A., Nadal, A., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65071-7 · Cited by 102
p53-Dependent and -Independent Functions of the Arf Tumor SuppressorPreprint
Sherr, C. J., Bertwistle, D., den Besten, W., KUO, M.-L., SUGIMOTO, M., Tago, K., Williams, R. T., Zindy, F., & Roussel, M. F. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.004 · Cited by 106
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 104
Early Events in Axon/Dendrite Polarization
Cheng, P., & Poo, M. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113618 · Cited by 107
p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
Lindström, M. S., Klangby, U., & Wiman, K. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204303 · Cited by 101
Nedd8-modification of Cul1 is promoted by Roc1 as a Nedd8-E3 ligase and regulates its stability
Morimoto, M., Nishida, T., Nagayama, Y., & Yasuda, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03051-6 · Cited by 98
Self-citationImproving cancer therapy by non-genotoxic activation of p53
Laı́n, S., & Lane, D. P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00063-7 · Cited by 99
Cell cycle regulatory functions of the human oncoprotein MDM2.
Deb, S. P. (2003) · PubMed · Cited by 96
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., & Haupt, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5869-5878.2001 · Cited by 94
Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation
Rhodes, S. D., He, Y., Smith, A. E., Jiang, L., Lu, Q., Mund, J. A., Li, X., Bessler, W., Qian, S., Dyer, W., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz095 · Cited by 97
MDM2 and MDMX can interact differently with ARF and members of the p53 family
Wang, X., Arooz, T., Siu, W. Y., Chiu, C. H. S., Lau, A., Yamashita, K., & Poon, R. Y. C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02124-x · Cited by 94
MicroRNA Regulation of Human Breast Cancer Stem Cells
Shimono, Y., Mukohyama, J., Nakamura, S.-I., & Minami, H. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm5010002 · Cited by 96
mdm2: a bridge over the two tumour suppressors, p53 and Rb
Yap, D., Hsieh, J.-K., Chan, F., & Lü, X. (1999) · Oncogene · doi:10.1038/sj.onc.1202954 · Cited by 93
Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization
Rizos, H., Darmanian, A., Mann, G. J., & Kefford, R. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203629 · Cited by 95
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2
Xirodimas, D. P., Chisholm, J., Desterro, J. M. S., Lane, D. P., & Hay, R. T. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03310-0 · Cited by 94
Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization
Saxena, A. D., Rorie, C. J., Dimitrova, D. D., Daniely, Y., & Borowiec, J. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209714 · Cited by 94
Li, D. W.-C., Liu, J.-P., Schmid, P. C., Schlosser, R., Feng, H., Liu, W.-B., Yan, Q., Gong, L., Sun, S.-M., Deng, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209334 · Cited by 98
Nuclear exclusion of p53 in a subset of tumors requires MDM2 function
Lu, W., Pochampally, R. R., Chen, L., Chomnawang, M. T., Wang, Y., & Chen, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203262 · Cited by 90
Ribosomal Protein S14 Negatively Regulates c-Myc Activity
Zhou, X. Y., Hao, Q., Liao, J., Liao, P., & Lu, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445122 · Cited by 97
Influence of p53 mutations on prognosis of patients with glioblastoma
Shiraishi, S., Tada, K., Nakamura, H., Makino, K., Kochi, M., Saya, H., Kuratsu, J., & Ushio, Y. (2002) · Cancer · doi:10.1002/cncr.10677 · Cited by 91
Contribution of two independent MDM2-binding domains in p14ARF to p53 stabilization
Lohrum, M. A. E., Ashcroft, M. A., Kubbutat, M. H. G., & Vousden, K. H. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00472-3 · Cited by 91
DNA Damage-induced Inhibition of Securin Expression Is Mediated by p53
Zhou, Y., Mehta, K. R., Choi, A., Scolavino, S., & Zhang, X. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203793200 · Cited by 91
Regulation and activation of p53 and its family members
Lohrum, M. A. E., & Vousden, K. H. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400625 · Cited by 91
Human ARF protein interacts with Topoisomerase I and stimulates its activity
Karayan, L., Riou, J., Seité, P., Migeon, J., Cantereau, A., & Larsen, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204170 · Cited by 89
A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection.
Zhu, J. W., DeRyckere, D., Li, F. X., Wan, Y. Y., & DeGregori, J. V. (1999) · PubMed · Cited by 89
Novel targets of Akt, p21, and MDM2
Zhou, B. P., & Hung, M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70128-0 · Cited by 88
Signal transduction pathways that contribute to myeloid differentiation
Miranda, M. B., & Johnson, D. E. (2007) · Leukemia · doi:10.1038/sj.leu.2404690 · Cited by 94
Strano, S., Rossi, M., Fontemaggi, G., Munarriz, E. R., Soddu, S., Sacchi, A., & Blandino, G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02119-6 · Cited by 87
Regulation of the 26S proteasome by adenovirus E1A
Turnell, A. S., Grand, R. J. A., Gorbea, C., Zhang, X., Wang, W., Mymryk, J. S., & Gallimore, P. H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4759 · Cited by 88
Migliorini, D., Danovi, D., Colombo, E., Carbone, R., Pelicci, P. G., & Marine, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108795200 · Cited by 88
Sasaki, M., Ikeda, H., Sato, Y., & Nakanuma, Y. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051237 · Cited by 87
The RING domain of Mdm2 can inhibit cell proliferation.
Dang, J., Kuo, M.-L., Eischen, C. M., Stepanova, L., Sherr, C. J., & Roussel, M. F. (2002) · PubMed · Cited by 86
Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein
Kimura, S. H., & Nojima, H. (2002) · Genes to Cells · doi:10.1046/j.1365-2443.2002.00564.x · Cited by 85
Replication-selective viruses for cancer therapy
Biederer, C. H., Ries, S. J., Brandts, C., & McCormick, F. P. (2001) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0295-1 · Cited by 86
Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma
Hedberg, M. L., Berry, C. T., Moshiri, A. S., Xiang, Y., Yeh, C. J., Atillasoy, C., Capell, B. C., & Seykora, J. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073478 · Cited by 94
Iqbal, J., Wilcox, R., Naushad, H., Rohr, J. M., Heavican, T. B., Wang, C., Bouska, A. C., Fu, K., Chan, W. C., & Vose, J. M. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.003 · Cited by 83
Versatile functions of p53 protein in multicellular organisms
Chumakov, P. M. (2007) · Biochemistry (Moscow) · doi:10.1134/s0006297907130019 · Cited by 85
p53 Activation by Nitric Oxide Involves Down-regulation of Mdm2
Wang, X., Michael, D., de MURCIA, G., & Oren, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112068200 · Cited by 84
Targeting p53-MDM2-MDMX Loop for Cancer Therapy
Zhang, Q., Zeng, S. X., & Lu, H. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_16 · Cited by 85
Ko, A., Han, S. Y., Choi, C. H., Cho, H., Lee, M.-S., Kim, S., Song, J. S., Hong, K., Lee, H., Hewitt, S. M., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0072-0 · Cited by 85
Acridine derivatives activate p53 and induce tumor cell death through bax
Wang, W., Ho, W. C., Dicker, D. T., MacKinnon, C., Winkler, J. D., Marmorstein, R., & El‐Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.8.2134 · Cited by 83
Balance of Yin and Yang: Ubiquitylation-Mediated Regulation of p53 and c-Myc
Dai, M., Jin, Y., Gallegos, J. R., & Lu, H. (2006) · Neoplasia · doi:10.1593/neo.06334 · Cited by 85
MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation
Jackson, M. W., Lindström, M. S., & Berberich, S. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010685200 · Cited by 74
Kelly‐Spratt, K. S., Gurley, K. E., Yasui, Y., & Kemp, C. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020242 · Cited by 84
Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase
Fujino, T., Watanabe, K., Beppu, M., Kikugawa, K., & Yasuda, H. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(00)00004-2 · Cited by 81
Self-citationMyc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts
Lindström, M. S., & Wiman, K. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206659 · Cited by 77
p53-Induced Apoptosis as a Safeguard against Cancer
Asker, C., Wiman, K. G., & Selivanova, G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1446 · Cited by 79
Estrogen receptor protects p53 from deactivation by human double minute-2.
Liu, G., Schwartz, J. A., & Brooks, S. C. (2000) · PubMed · Cited by 79
Binding of p53 to the Central Domain of Mdm2 Is Regulated by Phosphorylation
Kulikov, R., Winter, M., & Blattner, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513311200 · Cited by 79
Cell Transformation by Human Adenoviruses
Endter, C., & Dobner, T. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05599-1_6 · Cited by 80
Scission of the p53-MDM2 Loop by Ribosomal Proteins
Zhou, X. Y., Liao, J.-M., Liao, W.-J., & Lu, H. (2012) · Genes & Cancer · doi:10.1177/1947601912455200 · Cited by 82
Ser326Cys polymorphism inhOGG1 gene and risk of esophageal cancer in a Chinese population
Xing, D.-Y., Tan, W., Song, N., & Lin, D. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010520)95:3 · Cited by 153
Mutant p53 proteins bind DNA in a DNA structure-selective mode
hler, T. G. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76
DNA damage response to the Mdm2 inhibitor Nutlin-3
Verma, R., Rigatti, M. J., Belinsky, G. S., Godman, C. A., & Giardina, C. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.020 · Cited by 77
Immunolocalization of Human p14ARF to the Granular Component of the Interphase Nucleolus
Lindström, M. S., Klangby, U., Inoue, R., Pisa, P., Wiman, K. G., & Asker, C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4854 · Cited by 77
Inactivation of p53 and life span extension of human diploid fibroblasts by mot‐2
Kaul, S. C., Reddel, R. R., Sugihara, T., Mitsui, Y., & Wadhwa, R. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01594-5 · Cited by 76
Dumaz, N., Milne, D., Jardine, L., & Meek, D. W. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590459 · Cited by 75
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
Supiot, S., Hill, R. P., & Bristow, R. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0442 · Cited by 74
The p53 tumor suppressor: Critical regulator of life & death in cancer
Fisher, D. E. (2001) · APOPTOSIS · doi:10.1023/a:1009659708549 · Cited by 74
Buschmann, T., Lerner, D., Lee, C.-G., & Ronai, Z. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103786200 · Cited by 73
Lee, S., Tarn, C., Wang, W., Chen, S., Hullinger, R. L., & ANDRISANI, O. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108025200 · Cited by 73
Aberrant ubiquitin-mediatedproteolysis of cell cycle regulatory proteins and oncogenesis
Bashir, T., & Pagano, M. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)88305-7 · Cited by 73
DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer
Gjerset, R. A. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9040-y · Cited by 71
Castillo, J., Frame, F. M., Rogoff, H. A., Pickering, M., Yurochko, A. D., & Kowalik, T. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11467-11475.2005 · Cited by 72
Laı́n, S., Xirodimas, D. P., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4672 · Cited by 72
Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation
Zaika, A. I., Marchenko, N. D., & Moll, U. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27474 · Cited by 72
Kadoya, T., Yamamoto, H., Suzuki, T., Yukita, A., Fukui, A., Michiue, T., Asahara, T., Tanaka, K., Asashima, M., & Kikuchi, A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3803-3819.2002 · Cited by 71
p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53
Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., & Holubar, M. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5733 · Cited by 71
Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
Zhang, T., & Prives, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 70
Seavey, S. E., Holubar, M. K., Saucedo, L. J., & Perry, M. E. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7590-7598.1999 · Cited by 69
Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J. K., Addo, J. K., Kamath, S., Patil, S. A., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis
Maerken, T. V., Vandesompele, J., Rihani, A., Paepe, A. D., & Speleman, F. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.138 · Cited by 74
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Carr, M. I., & Jones, S. N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.75 · Cited by 71
Cell cycle regulatory E3 ubiquitin ligases as anticancer targets
Pray, T. R., Parlati, F., Huang, J., Wong, B. R., Payan, D. G., Bennett, M. K., Issakani, S. D., Molineaux, S. M., & Demo, S. D. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00121-8 · Cited by 66
Jab1 is a specificity factor for E2F1-induced apoptosisPreprint
Hallstrom, T. C., & Nevins, J. R. (2006) · Genes & Development · doi:10.1101/gad.1345006 · Cited by 67
Malonia, S. K., Dutta, P., Santra, M. K., & Green, M. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510929112 · Cited by 66
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 71
Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation
Kim, M., Tezuka, T., Tanaka, K., & Yamamoto, T. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207298 · Cited by 65
Thermodynamics of p53 Binding to hdm2(1–126): Effects of Phosphorylation and p53 Peptide Length
Lai, Z., Auger, K. R., Manubay, C. M., & Copeland, R. A. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1998 · Cited by 66
Association of p14ARF with the p120E4FTranscriptional Repressor Enhances Cell Cycle Inhibition
Rizos, H., Diefenbach, E., Badhwar, P., Woodruff, S., Becker, T. M., Rooney, R. J., & Kefford, R. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210978200 · Cited by 64
Mirzayans, R., Andrais, B., Kumar, P., & Murray, D. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050928 · Cited by 64
p16 and ARF: activation of teenage proteins in old age
Ande, S., & Rudolph, K. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci23437 · Cited by 64
A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2
Berger, M., Sionov, R. V., Levine, A. J., & Haupt, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008879200 · Cited by 64
CARF Is a Novel Protein That Cooperates with Mouse p19 (Human p14 ) in Activating p53
Hasan, M. K., Yaguchi, T., Sugihara, T., Kumar, P. K. R., Taira, K., Reddel, R. R., Kaul, S. C., & Wadhwa, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204177200 · Cited by 65
Bain, P. A., Shaw, G. R., & Patel, B. K. C. (2007) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390701434877 · Cited by 62
Essential Role of the B23/NPM Core Domain in Regulating ARF Binding and B23 Stability
Enomoto, T., Lindström, M. S., Jin, A., Ke, H., & Zhang, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602788200 · Cited by 62
Differential Regulation of E2F1, DP1, and the E2F1/DP1 Complex by ARF
Datta, A., Nag, A., & Raychaudhuri, P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8398-8408.2002 · Cited by 63
Hiroyasu, M., Ozeki, M., Kohda, H., Echizenya, M., Tanaka, T., Hiai, H., & Toyokuni, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64860-2 · Cited by 61
Metadata
- Authors
- Honda, R., & Yasuda, H.
- Affiliations
- Tokyo University of Pharmacy and Life Sciences (JP)
- Corresponding author
- Yasuda, Hideyo
- Venue
- The EMBO Journal
- Published
- 1999-01-04
- Volume
- 18
- Issue
- 1
- Pages
- 22-27
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC1171098
- OpenAlex
- W2028210102
- Cited by
- 724
- References
- 43
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 12 · 2022: 12 · 2021: 3 · 2020: 10 · 2019: 4 · 2018: 11 · 2017: 5 · 2016: 14 · 2015: 19 · 2014: 20 · 2013: 24 · 2012: 20
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The EMBO Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Molecular Biology Organization
- Institute of Genetics
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p19ARF, MDM2, p53, ubiquitin ligase activity, p53 ubiquitination, p53 stabilization, DNA-dependent protein kinase, p53 phosphorylation, DNA damage response, tumor suppressor proteins, protein-protein interaction
- MeSH terms
- Animals, Cell Line, Cloning, Molecular, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Phosphorylation, Proteins, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Ubiquitins, Tumor Suppressor Protein p53, Protein Serine-Threonine Kinases, Spodoptera, Tumor Suppressor Protein p14ARF, Ubiquitin-Protein Ligases, Proto-Oncogene Proteins c-mdm2, DNA-Activated Protein Kinase, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
